

Genomic imbalances in the placenta are associated with poor fetal growth

Giulia F. Del Gobbo

The University of British Columbia Faculty of Medicine

Yue Yin

Hospital for Sick Children

Sanaa Choufani

Hospital for Sick Children

Emma A. Butcher

Hospital for Sick Children

John Wei

Hospital for Sick Children

Evica Rajcan-Separovic

University of British Columbia

Hayley Bos

University of British Columbia

Peter von Dadelszen

King's College London

Rosanna Weksberg

The Hospital for Sick Children

Wendy P Robinson (✉ wrobinson@bcchr.ca)

University of British Columbia <https://orcid.org/0000-0002-2010-6174>

Ryan K.C. Yuen

The Hospital for Sick Children

Research article

Keywords: Aneuploidy, confined placental mosaicism, copy number variant, fetal growth restriction, placenta, pregnancy, small-for-gestational-age, trisomy

DOI: <https://doi.org/10.21203/rs.3.rs-40599/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Fetal growth restriction (FGR) is associated with increased risks for complications before, during, and after birth, in addition to risk of disease through to adulthood. Although placental insufficiency, failure to supply the fetus with adequate nutrients, underlies most cases of FGR, its causes are diverse and not fully understood. One of the few diagnosable causes of placental insufficiency in ongoing pregnancies is the presence of large chromosomal imbalances such as trisomy confined to the placenta; however, the impact of smaller copy number variants (CNVs) has not yet been adequately addressed. In this study, we confirm the importance of placental aneuploidy, and assess the potential contribution of CNVs to fetal growth.

Methods: We used molecular-cytogenetic approaches to identify aneuploidy in placentas from N=101 infants born small-for-gestational age (SGA), typically used as a surrogate for FGR, and from N=173 non-SGA controls from uncomplicated pregnancies. We confirmed aneuploidies and assessed mosaicism by microsatellite genotyping. We then profiled CNVs using high-resolution microarrays in a subset of N=53 SGA and N=61 control euploid placentas, and compared the load, impact, gene enrichment and clinical relevance of CNVs between groups. Candidate CNVs were confirmed using quantitative PCR.

Results: Aneuploidy was over 10-fold more frequent in SGA-associated placentas compared to controls (11.9% vs. 1.1%; $p=0.0002$, OR=11.4, 95% CI 2.5-107.4), was confined to the placenta, and typically involved autosomes, whereas only sex chromosome abnormalities were observed in controls. We found no significant difference in CNV load or number of placental-expressed or imprinted genes in CNVs between SGA and controls, however, a rare and likely clinically-relevant germline CNV was identified in 5.7% of SGA cases. These CNVs involved candidate genes *INHBB*, *HSD11B2*, *CTCF*, and *CSMD3*.

Conclusions: We conclude that placental genomic imbalances at the cytogenetic and submicroscopic level may underlie up to ~18% of SGA cases in our population. This work contributes to the understanding of the underlying causes of placental insufficiency and FGR, which is important for counselling and prediction of long term outcomes for affected cases.

Background

Fetal growth restriction (FGR), where the fetus does not grow to its genetic potential, affects 5-12% of pregnancies in developed countries (1). FGR is associated with increased risk for perinatal, neonatal, pediatric and long-term adult health complications (2–6). Often small-for-gestational age (SGA, birth weight <10th percentile) is used as a surrogate for FGR, however, a subset of SGA infants may be small but normally grown for their potential and thus otherwise healthy. In particular, pathologically growth-restricted infants are at increased risk for morbidity and mortality.

Poor growth *in utero* is most commonly attributed to placental insufficiency, however fetal infection or genetic abnormality, and maternal health or lifestyle factors may also play a role (7–9). Some of these factors (e.g. maternal smoking, infection, obesity) may also contribute to poor trophoblast development

and function, thus the etiologies of FGR and placental insufficiency are complex and intertwined. A major known cause of placental insufficiency in a viable pregnancy is confined placental mosaicism (CPM), where some or most cells in the placenta are aneuploid, while the fetus has a predominantly normal diploid chromosome complement. CPM identified prenatally is associated with increased risk for FGR and other pregnancy complications depending on the levels of abnormal cells and the chromosome(s) involved (10,11). Screening placentas postnatally has also confirmed a contribution of CPM to FGR (12–15). We previously identified trisomy CPM in 4/43 FGR pregnancies, but none in 85 controls nor 18 cases associated with preeclampsia (PE) without FGR (16). Despite the evidence that large genomic imbalances in the placenta are associated with FGR, few studies have investigated the role of smaller genetic imbalances (<5-10 Mb), copy number variants (CNVs). To date, studies investigating CNVs associated with FGR have either not studied placental tissue (17,18) or had small sample sizes and found conflicting results (19,20).

In this study, we aimed to thoroughly evaluate the contribution of placental genomic imbalances to poor fetal growth. To this end, we assessed i) the incidence of large aneuploidies (>15 Mb) in 274 placentas from control and SGA pregnancies, and ii) the load, impact, and clinical relevance of placental CNVs (<15 Mb) to SGA in a subset of 114 euploid placentas. This is the largest study to date of its kind; it enhances our understanding of the underlying causes of placental dysfunction and poor fetal growth, and further establishes the importance of assessment of CPM in the clinic.

Methods

Research ethics approval

Ethics approval for use of human research subjects in this study was obtained from the University of British Columbia/Children's and Women's Health Centre of British Columbia Research Ethics board (H17-01545) and from the Hospital for Sick Children (1000038847) and Mount Sinai Hospital (05-0038-E) Research Ethics boards. Informed written consent was obtained from all study participants.

Sample collection and cohort characteristics

Vancouver Cohort

Placental samples for the Vancouver cohort were ascertained and processed as described (16) and include cases used in previous studies (16,21–24). Clinical information, including newborn sex and birth weight, gestational age at delivery, maternal age, and ethnicity were collected. Placental and maternal samples were processed and DNA was extracted as previously described (16).

This cohort (N=207) included 136 controls from uncomplicated pregnancies (no SGA, hypertension/PE, or known abnormal maternal serum screen results) and 71 cases of SGA (**Table 1**). Exclusion criteria were a

prenatally-diagnosed chromosome abnormality or congenital anomaly in the fetus. SGA was defined as birth weight <10th percentile, adjusted for sex and gestational age at birth based on Canadian growth charts (25). The majority, 55/71 (77%) of SGA cases met criteria for FGR, defined as birth weight <3rd percentile, or <10th percentile with additional findings suggestive of placental insufficiency, including i) persistent uterine artery notching at 22-25 weeks, ii) absent or reversed end diastolic velocity on umbilical artery Doppler, and/or iii) oligohydramnios (amniotic fluid index <50 mm). One FGR case had a birth weight >10th percentile but was diagnosed as FGR from prenatal measurements and severe oligohydramnios. Preeclampsia (PE) was defined according to Canadian criteria(26) as previously described (24). A subset of SGA cases were associated with maternal PE (**Table 1**); the SGA cases associated with maternal PE delivered significantly earlier than those without (mean 33.2 weeks vs. 36.9 weeks, respectively; $p<0.05$, Mann-Whitney U-test), however birth weight did not differ ($p>0.05$, Student's t-test). Following aneuploidy assessment, euploid placentas from a subset of N=24 control and N=29 SGA cases, 90% of which fulfilled criteria for FGR, were selected for further CNV profiling (**Table 1**). These were randomly selected after excluding cases or controls associated with a twin pregnancy (N=23), or known maternal smoking during pregnancy (N=3/108 respondents). **Figure 1** summarizes the study design and number of cases per cohort used at each analysis step.

Toronto cohort

The Toronto cohort was ascertained and processed as part of a distinct study, and findings from the two cohorts were then subsequently compared. Placental samples were obtained as previously described (27). Clinical information including newborn sex, birth weight, and gestational age were collected for all cases. The original cohort included N=99 samples, however following microarray quality filtering, N=67 remained, including placentas from 37 control and 30 SGA pregnancies (**Table 1, Figure 1**). Definitions for control and SGA followed the same criteria as the Vancouver cohort, described above. Exclusion criteria were a prenatally-diagnosed chromosome abnormality or congenital anomaly in the fetus, CMV or toxoplasmosis infection, or clinical amnionitis. Additionally, cases or controls were excluded if mothers were diagnosed with: i) preconceptional severe hypertension; ii) clinically significant thrombophilia; iii) advanced renal, heart or liver failure; iv) type I diabetes mellitus or gestational diabetes requiring treatment with insulin; or v) anemia and autoimmune disorders requiring therapy during pregnancy. Maternal PE was not present in any of the cases in this cohort (**Table 1**)

Aneuploidy screening and CPM follow-up

Aneuploidy was detected using several methods in this study. In the Vancouver cohort, samples were assessed by comparative genomic hybridization (CGH), which can detect aneuploidies greater than 15 Mb, or by multiplexed ligation-dependent probe amplification (MLPA) of subtelomeric probes (SALSA MLPA Subtelomeres Mix, MRC-Holland, NL), designed to detect aneuploidies that extend to the ends of the chromosome (**Figure 1**). A subset of these samples (N=85 control and N=43 SGA), all screened by

CGH, have been previously published (16); the current study is a retrospective re-assessment of aneuploidy in those cases, with additional samples collected. For more recent cases, MLPA was used to screen for aneuploidy because it is a reliable and cost-effective method to identify whole chromosome aneuploidies (monosomy and trisomy), as well as terminal duplications and deletions. In the Toronto cohort, aneuploidy was detected using CNV profiling by microarray (see below). All cases with an aneuploidy detected by any method was further assessed by microsatellite polymorphism genotyping of probes on the involved chromosome (**Supplementary Methods**). Aneuploidies identified by MLPA were also confirmed using CNV profiling by microarray to determine the extent of the alteration, particularly in cases where results suggested abnormalities restricted to one chromosome arm (see below, **Supplementary Methods**).

Microarray processing and CNV detection

Placental DNA was assessed on the Infinium Omni2.5-8 BeadChip array (Illumina, USA) for the Vancouver cohort, and on the Affymetrix CytoScan HD array (ThermoFisher Scientific, USA) for the Toronto cohort (**Figure 1**) at The Centre for Applied Genomics, Toronto, Canada (28,29). In the Vancouver cohort, an additional DNA sample from a different location in each placenta was also run on the array to assess the possibility of detecting mosaicism of CNVs by high-density microarray (**Supplementary Methods**). Following sample quality checks unique to each array type, all 54 Vancouver cases and 67/99 Toronto cases were available for analysis (**Figure 1**). CNVs were detected using in-house pipelines (28,29) applying 3-4 CNV-calling algorithms specific to each array platform (**Supplementary Methods**). Following CNV quality checks, high-confidence CNVs called by at least two algorithms with a minimum 50% reciprocal overlap, ≥ 5 probes, and ≥ 10 kb were kept for analysis. CNV boundaries were compared to the Database of Genomic Variants and in-house databases of CNVs in controls, and rare CNVs were defined as those present in $<0.1\%$ of controls and at least 50% unique. Given discordance in CNV calls between technical replicates of placental DNA (**Supplementary Methods, Supplementary Figure 1**), mosaicism of CNVs was not investigated and the DNA sample with the higher microarray quality scores from each placenta was selected for CNV analysis for the Vancouver cohort. Ancestry was assessed using SNP genotypes by MDS clustering of identity-by-state distances in PLINK (30) (**Supplementary Methods**). The ancestry composition of both cohorts was comparable (**Supplementary Table 1, Supplementary Figure 2**).

Candidate CNVs

CNVs with potential clinical relevance to SGA were prioritized based on: whether they were rare, ≥ 200 kb, overlap pathogenic or likely pathogenic CNVs in the DECIPHER or ClinVar databases, overlap genes with important roles in placental function or those that are reported to be differentially expressed or with variants associated with growth restriction. CNVs were categorized following American College of Medical Genetics guidelines (31). Candidate CNVs were confirmed and assessed for CPM using quantitative PCR (**Supplementary Methods**).

Placental-enhanced and imprinted genes

A list of 356 genes with elevated expression in the placenta was downloaded from the Human Protein Atlas (32), including 78 with placental-specific elevated expression. A database of imprinted regions was curated from the OTAGO Imprinted Genes (33) and GenImprint (34) databases, and reported placental imprinted differentially methylated regions (DMRs)(35,36) (**Table S2**). Outer genomic boundaries were used to generate a consensus region for those genes associated with a placental imprinted DMR.

Functional pathway enrichment

Enrichment of 2,191 GO and KEGG (37) pathways in genes with coding sequences impacted by rare CNVs in SGA was assessed using a generalized linear model with universal gene count correction in the *cnvGSA* R package. Sex and cohort (array) were included as covariates, and thresholds of 100-1,500 genes were used to limit pathways assessed. A false-discovery rate (FDR) of <0.1 was used to define significantly enriched (coefficient>0) or deficient (coefficient<0) pathways in SGA CNVs.

Statistical analyses

Continuous variables were compared using the Student's t-test or Mann-Whitney U test depending on whether the data was normally-distributed by the Shapiro-Wilk normality test. Categorical variables were compared by Fisher's exact test. Bonferroni correction for multiple testing was used where applicable. Statistical power for comparing CNV load was assessed using the *pwr* package in R. Based on a previous report of a large effect size ($d>0.95$) in the difference in CNV load in control vs. SGA placentas (19), we assumed a slightly lower but still large effect size (d) of 0.8. Based on the minimum sample size in each group per cohort (N=24) and using an $\alpha=0.05$, our study had >80% power to detect significant differences in each cohort individually. Analyses were performed in R version 3.5.1 (38), and plots were generated using the *ggplot2*, *ggbio*, and *ggpubr* packages.

Results

Poor fetal growth is associated with placental aneuploidy

Aneuploidy screening was performed in 207 placentas from the Vancouver cohort and 67 placentas passing microarray quality checks from the Toronto cohort. Amongst 173 control placentas, no cases of CPM or autosomal aneuploidy were detected. Two (1.1%) controls had constitutional abnormalities involving the sex chromosomes (**Table 2**), one of which only impacted Yqter. In contrast, amongst 101 SGA cases, 12 (11.9%) had a whole or partial autosomal trisomy present in the placenta (**Table 2**) ($p=0.00017$; OR=11.4, 95% CI=2.5-107.4; Fisher's exact test). Placental autosomal aneuploidies were found both in cases of isolated SGA (N=9/70; 12.8%) and cases of SGA with maternal PE (N=3/31; 9%).

Of the cases with successful follow-up (10/12), all abnormalities in SGA placentas were determined to be CPM based on microsatellite genotyping (**Table 2**). Four of these cases were previously published¹⁹, however 8 are new and confirm the association between CPM and SGA. Of the 9 cases with available maternal DNA, uniparental disomy (UPD) was excluded in the diploid cell population from all but one previously-published case with CPM for trisomy 2 and probable upd(2)mat (16). The incidence of aneuploidy did not differ between cohorts (2/136 vs. 0/37 controls and 7/71 vs. 5/30 SGA in the Vancouver and Toronto cohorts, respectively). Overall, our cohorts had high maternal ages (**Table 1**), and among the SGA cases, maternal age tended to be higher in pregnancies associated with CPM than those without a placental aneuploidy (**Supplementary Table 3**), though this was not significant ($p>0.05$, Student's t-test).

Load of CNVs does not differ between SGA and control placentas

To explore the role of placental CNVs in *in utero* growth, 114 euploid placentas from control and SGA newborns were assessed using high-density microarrays (**Figure 1**). We found one SGA case (PM324) with mosaicism for 8 large 2-4 Mb duplications in the placenta (**Supplementary Figure 3**). As the combined level of aneuploidy exceeded 27 Mb, it was an outlier that was excluded from further comparisons, so as to not bias results; we instead considered it as an additional case of placental segmental aneuploidy. Due to significant differences in load of CNVs between the different array platforms (**Supplementary Table 4**), we performed case-control comparisons within each cohort independently. We found no difference in total number and cumulative extent (bp) of CNVs per placenta, except for a greater cumulative bp of rare CNVs in SGA placentas in the Vancouver cohort ($p=0.03$, Mann-Whitney U test) (**Table 3**). When comparing these measures by gains and losses separately, there were also no significant differences (**Table 3**).

As larger CNVs are more likely to be impactful, we compared CNV size across all placentas in each group. In the Vancouver cohort, CNVs were larger in SGA placentas ($p=0.002$, Mann-Whitney U test; **Supplementary Figure 4**). When considering CNV gains and losses separately, only the losses were significantly larger ($p=0.010$, Mann-Whitney U test; **Supplementary Figure 4**). When separated by sex, the larger CNV sizes in SGA were significant only amongst females (**Supplementary Figure 5**). There were no significant differences between groups in the Toronto cohort.

To further assess whether SGA placentas had a greater CNV load, we compared the number of gains or losses per placenta at size bins ranging from <15 kb to >3 Mb in all CNVs or only in rare CNVs between groups. There were no consistent differences between SGA and control placentas. SGA placentas in the Vancouver cohort had fewer small losses (<15 kb, $p=0.002$; Mann-Whitney U-test), and those in the Toronto cohort had more large losses (500 kb-1 Mb, $p=0.001$; Mann-Whitney U-test). Both of these findings withstood multiple test corrections at a Bonferroni-corrected p -value threshold of $p=0.005$, but were not observed in rare CNVs (**Figure 2**).

Candidate CNVs identified in SGA placentas

We next focused on rare CNVs ≥ 200 kb as these are most likely to contribute to the SGA phenotype. There were 34 large rare CNVs present in SGA placentas and 53 in controls. CNVs with potential roles in placental function and/or fetal growth were identified 5.7% (3/53) of SGA placentas but not in controls (0/61). The SGA cases carrying a candidate CNV were all isolated SGA without maternal PE. The 3 candidate CNVs were categorized as variants of uncertain significance (VUS)-likely pathogenic and impact the functionally relevant genes *IHNBB*, *HSD11B2*, *CTCF*, and *CSMD3* (**Table 4**). These were confirmed by qPCR to be present in both placenta and cord blood, thus were not confined to the placenta.

No difference in total, placental-enhanced, or imprinted genes impacted by placental CNVs

To investigate potential impact of CNVs, we compared the number of genes involved in CNVs per case. We found no differences in the Vancouver cohort, however there was a trend for a greater number of genes affected by losses in SGA placentas in the Toronto cohort ($p=0.049$, Mann-Whitney U-test; **Figure 3**). There were no significant differences when focusing on rare CNVs.

We did not find an enrichment of genes with enhanced placental expression in SGA CNVs, however there were more losses of placental-enhanced genes in controls in the Toronto cohort ($p=0.02$, Fisher's exact test; **Supplementary Table 5**) that was not reproduced in the Vancouver cohort. Gains impacting *ERVV-1* and *ERVV-2*, and CNVs impacting several *PSG* family genes, a region known to be copy number variable in the human population(39), were common in both cases and controls.

We did not find any significant enrichment of imprinted regions in placental CNVs from SGA cases (**Supplementary Table 6**). Several common CNVs impacting imprinted regions were recurrent, including placental imprinted DMRs for *SPRN* and *CYP2E1* (**Supplementary Table 7**). CNVs deemed as rare were also recurrent, including gains impacting *KCNK9* and the DMR near *PRMT2* (**Supplementary Table 7**). One rare CNV was present uniquely in a SGA case, arr[hg19] 22q11.21(19,931,668-19,980,300)x1, overlapping the placental-specific imprinted DMR and coding sequence of *ARVCF*. One other CNV resulted in a deletion of the growth-related gene *INS* in a control: arr[hg19] 11q15.5(2,170,670-2,199,458)x1 (**Supplementary Table 7**).

No significantly enriched gene pathways in SGA CNVs

Out of 1,872 GO and KEGG pathways with genes involved in rare CNVs, we did not find any significantly enriched pathways in SGA CNVs (FDR>0.4). 8 pathways were enriched at a nominal $p<0.05$, the top being "negative regulation of cell cycle" ($p=0.031$), and 7 were deficient (**Supplementary Table 8**). Investigating gains and losses separately, no enriched pathways were identified (FDR>0.4). 10 pathways were enriched

in SGA gains at a nominal $p < 0.05$, the top being “regulation of cellular response to stress” ($p = 0.009$), and three pathways were deficient in SGA gains (**Supplementary Table 8**).

Discussion

In this study, we investigated the contribution of genomic imbalances in the placenta to poor fetal growth. In our otherwise low-risk population, we found that CPM involving trisomy or large segmental aneuploidy was present in 11.9% of SGA cases, or 12.7% when including the case with duplications totaling >27 Mb. Placental aneuploidy was present at similar rates in SGA whether or not maternal PE was also present (isolated SGA: 12.8%, SGA with PE: 9.7%), although a greater sample size is needed to accurately compare these incidences. The significant association of trisomy CPM to SGA/FGR confirms previous reports (12–16), however we have additionally identified cases of CPM of large segmental aneuploidies contributing to SGA, including a $\text{dup}(7)(q21.2q36.3)$, $\text{del}(X)(p22.2)$ likely deriving from a X;7 translocation event, and a case with $\text{dup}(4)(p16.3p15.31)$, $\text{del}(4)(q34.2)$. Although CPM can occur in healthy pregnancies (14,40–42), only non-mosaic aneuploidies affecting the sex chromosomes were identified in our controls.

The incidence of placental aneuploidy associated with SGA in this study is comparable to past reports (13,15,16), however it is expected to be population-dependent. The frequency of trisomy, and thus CPM, increases with advanced maternal age, which is also a risk factor for SGA. Indeed, we found that maternal age tended to be higher in SGA pregnancies with CPM (mean: 36.7 y) than those that were chromosomally-balanced (mean: 35.0 y). Conversely, CPM should contribute to fewer cases of SGA in populations with high rates of other risk factors for SGA, such as maternal smoking or poor nutrition (43,44). A higher CPM incidence is also expected using a stricter definition of FGR rather than SGA, e.g. fetal weight $<3^{\text{rd}}$ percentile or by using biomarkers like placental growth factor (PIGF) in maternal serum that are predictive of placental-mediated FGR (45). Although we could not measure maternal PIGF levels, our SGA group was likely enriched for cases of pathological growth restriction as a large proportion of cases were $<3^{\text{rd}}$ percentile (68% Toronto cohort, 48% Vancouver cohort) and the majority of cases in the Vancouver cohort met criteria for FGR.

Overall, we could not confirm previous reports finding decreased (19) or increased (20) load of CNVs in SGA placentas compared to controls. Small sample size may explain these discrepancies, as both past studies had <10 cases per group. With greater sample size and low incidence of other risk factors in our population, we were well poised to detect genetic contributors to SGA. Although we identified trends that suggest that some SGA placentas have an increased load of large CNVs, our findings did not support that placental CNVs commonly contribute to SGA. We also did not find significant differences in number of total or placental-expressed genes or imprinted regions in CNVs, which also suggests that either these are not major drivers of poor fetal growth in our cohort or their effects are subtler than we had power to detect.

Nonetheless, a candidate VUS-likely pathogenic germline CNV was identified in 5.7% of SGA placentas in this study, all of which were SGA in the absence of maternal PE. This incidence is similar to past studies of prenatal samples, which identified pathogenic CNVs in 3-7% of cases of isolated FGR with normal karyotypes (17,18,46). Case 7665 has a duplication of *INHBB*, which encodes a subunit for the activin and inhibin proteins that play important roles in trophoblast growth and invasion (47,48), and altered mRNA or protein levels of these compounds are associated with miscarriage, severe PE, and FGR (49). Case 6234 has a deletion encompassing *HSD11B2* and part of *CTCF*. *HSD11B2* is highly expressed in placental trophoblast cells, and encodes 11 β -HSD2, which regulates fetal exposure to maternal glucocorticoids (50). Reduced placental *HSD11B2* gene expression or protein levels has been associated with FGR (51–54), and patients with rare mutations in *HSD11B2* have significantly lower birth weight (55). *CTCF* is a highly-conserved transcription factor, and rare loss-of-function variants or deletions of the gene are associated with low birth weight, postnatal growth retardation, microcephaly and intellectual disability (56). Case 10506 had a 3 Mb deletion encompassing *CSMD3*, which is reported to be intolerant to loss-of-function variants (upper bound o/e=0.3 in gnomAD (57)), and *Csmd3* knockout mice display lower body length and body fat (58).

Strengths and limitations

This is the first study to our knowledge to characterize both aneuploidy and copy number variants in the placenta in association with poor fetal growth. It also contributes the largest sample evaluated for the association between placental CNVs and SGA to date. This CNV assessment was comprehensive, as we incorporated rigorous data processing following well-established pipelines, and several thorough lines of investigation to establish the copy number profile of the placenta in association with SGA, as well as potential clinical relevance of CNVs to poor fetal growth.

Due to the retrospective nature of this study, differences exist in clinical characteristics and methodologies between the cohorts and are a limitation of the study. Certain exclusion criteria used in the Toronto cohort were not available in the Vancouver cohort (e.g. infection during pregnancy), therefore we could not exclude such cases. Additionally, some cases of SGA in the Vancouver cohort were associated with maternal PE whereas all Toronto cohort cases were of isolated SGA. Aneuploidy screening methods used were also not equivalent, as MLPA cannot detect large interstitial duplications or deletions. Despite this, the Vancouver and Toronto cohorts had similar clinical characteristics (**Table 1, Supplementary Table 1**) and the methods to screen for aneuploidy all accurately identify whole chromosome or chromosome arm abnormalities, therefore we combined the cohorts to improve our power to establish the contribution of placental aneuploidy to SGA. A limited number of placental biopsies were used to screen for aneuploidy in both cohorts, therefore it is likely that aneuploidies present at low levels or in a limited distribution in the placenta were missed.

Unlike the aneuploidy assessment, we were unable to combine the two cohorts to study CNV load associated with SGA due to the significant differences between the high-density microarrays used for

CNV detection. However even when assessed separately, each cohort had adequate power to identify differences at the large effect sizes described in previous reports (19,20), and testing the two cohorts independently gave us the opportunity to assess the reproducibility of our findings.

Research and clinical implications

An appreciation for the association between placental aneuploidy and SGA/FGR is relevant for both research and clinical applications. For studies investigating the etiology of idiopathic SGA/FGR, excluding cases explained by CPM may increase the power of association studies. When identified prenatally, CPM may signify that the pregnancy is at increased risk for complications depending on the extent of the abnormality and the chromosome(s) involved. For example, CPM of trisomy 8 has low risk of complications (59), while that of trisomy 16 is associated with a high risk for FGR and PE (10,60–62). There is also an increased risk of UPD in the diploid cell population, which can be associated with imprinting disorders; for example, $\text{upd}(7)\text{mat}$ and $\text{upd}(20)\text{mat}$ are associated with FGR and several long-term health complications (63,64). Reassuringly, follow-up studies of cases of CPM without UPD suggest that most growth-restricted infants tend to have catch-up growth, normal neurodevelopment, and no global developmental delay (41,65–67). Identifying cases that were growth-restricted due to CPM can inform further long-term outcome studies, particularly in relation to specific trisomies, to improve our understanding of the developmental trajectories and risks for complications in affected infants, and address the clinical utility of screening for CPM and UPD in cases of FGR.

Our findings also provide evidence that CNVs impacting genes relevant to growth or placental function may contribute to idiopathic SGA. In contrast to findings of aneuploidy CPM, the CNVs identified in our study were germline alterations and may therefore have clinical implications beyond birth. Future studies profiling CNVs associated with SGA or FGR may add to ours and improve the annotation of CNVs found in cases of obstetric complications, for which information is largely absent in population databases. Given the widespread use of non-invasive methods to detect placental DNA in maternal blood and the development of methods to identify CNVs from these samples (68–70), the feasibility of identifying pathogenic CNVs prenatally is increasing. This will have relevant implications for both predicting pregnancies at risk of FGR and its associated complications and for post-natal counselling if CNVs are not confined to the placenta. Additional research on the incidence and impact of CNVs on obstetric outcomes is thus needed to assess the potential clinical utility of this information.

Conclusions

Overall, we find consistent evidence that trisomy and segmental aneuploidy confined to the placenta are associated with a significant proportion of cases of poor fetal growth, and that rare germline CNVs overlapping genes of functional interest may also underlie a subset of idiopathic SGA cases. Together, these genomic imbalances may explain approximately 18% of SGA cases in our study population, and additional studies to evaluate the clinical utility of screening for these abnormalities are warranted.

Increased placental CNV load may not commonly impact fetal growth, however studies with larger sample sizes may help elucidate whether subgroups of SGA/FGR are linked to placental CNV load.

Abbreviations

CGH, comparative genomic hybridization; CNV, copy number variant; CPM, confined placental mosaicism; DMR, differentially methylated region; FDR, false-discovery rate; FGR, fetal growth restriction; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MDS, multidimensional scaling; MLPA, multiplexed ligation-dependent probe amplification; PE, preeclampsia; PIGF, Placental growth factor; SGA, small-for-gestational age; SNP, single nucleotide polymorphism; UPD, uniparental disomy; VUS, variant of uncertain significance

Declarations

Ethics approval and consent to participate

Ethics approval for use of human research subjects in this study was obtained from the University of British Columbia/Children's and Women's Health Centre of British Columbia Research Ethics board (H17-01545) and from the Hospital for Sick Children (1000038847) and Mount Sinai Hospital (05-0038-E) Research Ethics boards. Informed written consent was obtained from all study participants.

Consent for publication

Not applicable.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing interests

The authors report no conflict of interest.

Funding

This work was supported by a Canadian Institutes of Health Research (CIHR) grant to WPR [F16-04459] and a Thrasher Research Fund Early Career Award to RKC [12745]. WPR receives salary support through

an investigatorship award from the BC Children's Hospital Research Institute, RKCYS receives support from SickKids Catalyst Scholar in Genetics, and GFDG receives support from a CIHR Doctoral Fellowship.

Author's contributions

GFDG contributed to the study design, prepared samples for microarray, performed microsatellite genotyping and data analysis, interpreted results, and wrote the manuscript draft. YY and EAB contributed to data analysis. JW performed initial data processing. SC prepared samples for microarray analysis and collected clinical information. RW provided samples and clinical information. PVD and HB contributed to subject recruitment. ERS contributed to study design, and interpretation of results. RKCYS and WPR conceived the study and contributed to the data analysis and interpretation of results. All authors read and provided critical revisions of the manuscript and approve the final version.

Acknowledgements

We thank all study participants for the generous donation of samples. We thank Dr. Sylvie Langlois, Luana Avila, Kristal Louie, Dr. Johanna Schuetz, Ruby Jiang, Dr. Maria Peñaherrera, and the Research Centre for Women's and Infants' Health BioBank at the Samuel Lunenfeld Research Institute and the Mount Sinai Hospital/University Health Network Department of Obstetrics & Gynaecology for acquisition and processing of samples. We thank Dr. Chao Lu, Dr. Bhooma Thiruvahindrapuram, Dr. Suzi Walker, Dr. Tara Paton, and The Centre for Applied Genomics at The Hospital for Sick Children for technical support. We also thank Ruby Jiang and Dr. Maria Peñaherrera for their contribution and support of MLPA and microsatellite genotyping, and members of the Robinson lab for thoughtful discussions and feedback regarding data analysis and the manuscript.

References

1. Kramer MS. The epidemiology of adverse pregnancy outcomes: an overview. *J Nutr.* 2003;133(5 Suppl 2):1592S-1596S.
2. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. *Lancet Lond Engl.* 1993;341(8850):938–41.
3. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. *Am J Obstet Gynecol.* 2000;182(1):198–206.
4. Leitner Y, Fattal-Valevski A, Geva R, Bassan H, Posner E, Kutai M, et al. Six-year follow-up of children with intrauterine growth retardation: long-term, prospective study. *J Child Neurol.* 2000;15(12):781–6.
5. Breeze AC, Lees CC. Prediction and perinatal outcomes of fetal growth restriction. *Semin Fetal Neonatal Med.* 2007;12(5):383–97.

6. von Beckerath AK, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P. Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction. *Am J Obstet Gynecol.* 2013;208(2):130.e1-130.e6.
7. Roberts JM, Escudero C. The placenta in preeclampsia. *Pregnancy Hypertens.* 2012;2(2):72–83.
8. Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. *Am J Obstet Gynecol.* 2018;218(2S):S745–61.
9. Sharma D, Shastri S, Sharma P. Intrauterine Growth Restriction: Antenatal and Postnatal Aspects. *Clin Med Insights Pediatrics.* 2016;10:67–83.
10. Robinson WP, Barrett IJ, Bernard L, Telenius A, Bernasconi F, Wilson RD, et al. Meiotic origin of trisomy in confined placental mosaicism is correlated with presence of fetal uniparental disomy, high levels of trisomy in trophoblast, and increased risk of fetal intrauterine growth restriction. *Am J Hum Genet.* 1997;60(4):917–27.
11. Grati FR, Ferreira J, Benn P, Izzi C, Verdi F, Vercellotti E, et al. Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA. *Genet Med Off J Am Coll Med Genet.* 2019;s41436-y.
12. Artan S, Basaran N, Hassa H, Ozalp S, Sener T, Sayli BS, et al. Confined placental mosaicism in term placentae: analysis of 125 cases. *Prenat Diagn.* 1995;15(12):1135–42.
13. Krishnamoorthy A, Gowen LC, Boll KE, Knuppel RA, Sciorra LJ. Chromosome and interphase analysis of placental mosaicism in intrauterine growth retardation. *J Perinatol Off J Calif Perinat Assoc.* 1995;15(1):47–50.
14. Wilkins-Haug L, Roberts DJ, Morton CC. Confined placental mosaicism and intrauterine growth retardation: a case-control analysis of placentas at delivery. *Am J Obstet Gynecol.* 1995;172(1 Pt 1):44–50.
15. Stipoljev F, Latin V, Kos M, Miskovic B, Kurjak A. Correlation of confined placental mosaicism with fetal intrauterine growth retardation. A case control study of placentas at delivery. *Fetal Diagn Ther.* 2001;16(1):4–9.
16. Robinson WP, Penaherrera MS, Jiang R, Avila L, Sloan J, McFadden DE, et al. Assessing the role of placental trisomy in preeclampsia and intrauterine growth restriction. *Prenat Diagn.* 2010;30(1):1–8.
17. Zhu H, Lin S, Huang L, He Z, Huang X, Zhou Y, et al. Application of chromosomal microarray analysis in prenatal diagnosis of fetal growth restriction. *Prenat Diagn.* 2016;36(7):686–92.
18. Borrell A, Grande M, Meler E, Sabria J, Mazarico E, Munoz A, et al. Genomic Microarray in Fetuses with Early Growth Restriction: A Multicenter Study. *Fetal Diagn Ther.* 2017;42(3):174–80.
19. Kasak L, Rull K, Vaas P, Teesalu P, Laan M. Extensive load of somatic CNVs in the human placenta. *Sci Rep.* 2015;5:8342.
20. Biron-Shental T, Sharony R, Shtorch-Asor A, Keiser M, Sadeh-Mestechkin D, Laish I, et al. Genomic Alterations Are Enhanced in Placentas from Pregnancies with Fetal Growth Restriction and Preeclampsia: Preliminary Results. *Mol Syndromol.* 2016;6(6):276–80.

21. Yuen RK, Penaherrera MS, von Dadelszen P, McFadden DE, Robinson WP. DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. *Eur J Hum Genet EJHG*. 2010;18(9):1006–12.
22. Blair JD, Yuen RK, Lim BK, McFadden DE, von Dadelszen P, Robinson WP. Widespread DNA hypomethylation at gene enhancer regions in placentas associated with early-onset pre-eclampsia. *Mol Hum Reprod*. 2013;19(10):697–708.
23. Wilson SL, Leavey K, Cox BJ, Robinson WP. Mining DNA methylation alterations towards a classification of placental pathologies. *Hum Mol Genet*. 2018;27(1):135–46.
24. Del Gobbo GF, Price EM, Hanna CW, Robinson WP. No evidence for association of MTHFR 677C>T and 1298A>C variants with placental DNA methylation. *Clin Epigenetics*. 2018;10:34–1.
25. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved population-based Canadian reference for birth weight for gestational age. *Pediatrics*. 2001;108(2):E35.
26. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol Can JOGC*. 2014;36(5):416–41.
27. Ferreira JC, Choufani S, Grafodatskaya D, Butcher DT, Zhao C, Chitayat D, et al. WNT2 promoter methylation in human placenta is associated with low birthweight percentile in the neonate. *Epigenetics*. 2011;6(4):440–9.
28. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T, et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. *Nat Biotechnol*. 2011;29(6):512–20.
29. Uddin M, Thiruvahindrapuram B, Walker S, Wang Z, Hu P, Lamoureux S, et al. A high-resolution copy-number variation resource for clinical and population genetics. *Genet Med Off J Am Coll Med Genet*. 2015;17(9):747–52.
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81(3):559–75.
31. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST, Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med Off J Am Coll Med Genet*. 2011;13(7):680–5.
32. The Human Protein Atlas consortium. The Human Protein Atlas Tissue Atlas: Placenta [Internet]. [cited 2019 Jul 19]. Available from: <https://www.proteinatlas.org/humanproteome/tissue/placenta>
33. OTAGO Human Imprinted Gene Catalogue [Internet]. [cited 2018 Oct 25]. Available from: <http://igc.otago.ac.nz/home.html>
34. GeneImprint Human Imprinted Gene Database [Internet]. [cited 2018 Oct 25]. Available from: <http://www.geneimprint.com/site/genes-by-species.Homo+sapiens>

35. Court F, Tayama C, Romanelli V, Martin-Trujillo A, Iglesias-Platas I, Okamura K, et al. Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment. *Genome Res.* 2014;24(4):554–69.
36. Hanna CW, Penaherrera MS, Saadeh H, Andrews S, McFadden DE, Kelsey G, et al. Pervasive polymorphic imprinted methylation in the human placenta. *Genome Res.* 2016;26(6):756–67.
37. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000;28(1):27–30.
38. R Core Team. R: A language and environment for statistical computing. 2016;(Computer Program). Available from: <https://www.R-project.org/>
39. Chang CL, Semyonov J, Cheng PJ, Huang SY, Park JI, Tsai HJ, et al. Widespread divergence of the CEACAM/PSG genes in vertebrates and humans suggests sensitivity to selection. *PLoS One.* 2013;8(4):e61701.
40. Wapner RJ, Simpson JL, Golbus MS, Zachary JM, Ledbetter DH, Desnick RJ, et al. Chorionic mosaicism: association with fetal loss but not with adverse perinatal outcome. *Prenat Diagn.* 1992;12(5):347–55.
41. Fryburg JS, Dimaio MS, Yang-Feng TL, Mahoney MJ. Follow-up of pregnancies complicated by placental mosaicism diagnosed by chorionic villus sampling. *Prenat Diagn.* 1993;13(6):481–94.
42. Toutain J, Labeau-Gauzere C, Barnetche T, Horovitz J, Saura R. Confined placental mosaicism and pregnancy outcome: a distinction needs to be made between types 2 and 3. *Prenat Diagn.* 2010;30(12–13):1155–64.
43. Blatt K, Moore E, Chen A, Van Hook J, DeFranco EA. Association of reported trimester-specific smoking cessation with fetal growth restriction. *Obstet Gynecol.* 2015;125(6):1452–9.
44. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet Lond Engl.* 2013;382(9890):427–51.
45. Benton SJ, McCowan LM, Heazell AE, Gynspan D, Hutcheon JA, Senger C, et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. *Placenta.* 2016;42:1–8.
46. Shaffer LG, Rosenfeld JA, Dabell MP, Coppinger J, Bandholz AM, Ellison JW, et al. Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound. *Prenat Diagn.* 2012;32(10):986–95.
47. Bearfield C, Jauniaux E, Groome N, Sargent IL, Muttukrishna S. The secretion and effect of inhibin A, activin A and follistatin on first-trimester trophoblasts in vitro. *Eur J Endocrinol.* 2005;152(6):909–16.
48. Li Y, Klausen C, Cheng J-C, Zhu H, Leung PCK. Activin A, B, and AB increase human trophoblast cell invasion by up-regulating N-cadherin. *J Clin Endocrinol Metab.* 2014;99(11):E2216–25.
49. Wijayarathna R, de Kretser DM. Activins in reproductive biology and beyond. *Hum Reprod Update.* 2016;22(3):342–57.

50. Krozowski Z, MaGuire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. *J Clin Endocrinol Metab.* 1995;80(7):2203–9.
51. McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, et al. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. *J Clin Endocrinol Metab.* 2001;86(10):4979–83.
52. Dy J, Guan H, Sampath-Kumar R, Richardson BS, Yang K. Placental 11beta-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth Restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery. *Placenta.* 2008;29(2):193–200.
53. Zhao Y, Gong X, Chen L, Li L, Liang Y, Chen S, et al. Site-specific methylation of placental HSD11B2 gene promoter is related to intrauterine growth restriction. *Eur J Hum Genet.* 2014;22(6):734–40.
54. Lazo-de-la-Vega-Monroy ML, Solis-Martinez MO, Romero-Gutierrez G, Aguirre-Arzola VE, Wrobel K, Wrobel K, et al. 11 Beta-Hydroxysteroid Dehydrogenase 2 Promoter Methylation is Associated with Placental Protein Expression in Small for Gestational Age Newborns. *Steroids.* 2017;124:60–6.
55. Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. *J Clin Endocrinol Metab.* 1998;83(7):2244–54.
56. Gregor A, Oti M, Kouwenhoven EN, Hoyer J, Sticht H, Ekici AB, et al. De novo mutations in the genome organizer CTCF cause intellectual disability. *Am J Hum Genet.* 2013;93(1):124–31.
57. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020 May 1;581(7809):434–43.
58. Bult CJ, Blake JA, Smith CL, Kadin JA, Richardson JE, Mouse Genome Database Group. Mouse Genome Database (MGD) 2019. *Nucleic Acids Res.* 2019;47(D1):D801–6.
59. Cassina M, Calo A, Salviati L, Alghisi A, Montaldi A, Clementi M. Prenatal detection of trisomy 8 mosaicism: Pregnancy outcome and follow up of a series of 17 consecutive cases. *Eur J Obstet Gynecol Reprod Biol.* 2018;221:23–7.
60. Yong PJ, Langlois S, von Dadelszen P, Robinson W. The association between preeclampsia and placental trisomy 16 mosaicism. *Prenat Diagn.* 2006;26(10):956–61.
61. Benn P. Trisomy 16 and trisomy 16 Mosaicism: a review. *Am J Med Genet.* 1998;79(2):121–33.
62. Yong PJ, Barrett IJ, Kalousek DK, Robinson WP. Clinical aspects, prenatal diagnosis, and pathogenesis of trisomy 16 mosaicism. *J Med Genet.* 2003;40(3):175–82.
63. Kotzot D, Schmitt S, Bernasconi F, Robinson WP, Lurie IW, Ilyina H, et al. Uniparental disomy 7 in Silver-Russell syndrome and primordial growth retardation. *Hum Mol Genet.* 1995;4(4):583–7.
64. Mulchandani S, Bhoj EJ, Luo M, Powell-Hamilton N, Jenny K, Gripp KW, et al. Maternal uniparental disomy of chromosome 20: a novel imprinting disorder of growth failure. *Genet Med Off J Am Coll*

Med Genet. 2016;18(4):309–15.

65. Amor DJ, Neo WT, Waters E, Heussler H, Pertile M, Halliday J. Health and developmental outcome of children following prenatal diagnosis of confined placental mosaicism. *Prenat Diagn.* 2006;26(5):443–8.
66. Langlois S, Yong PJ, Yong SL, Barrett I, Kalousek DK, Miny P, et al. Postnatal follow-up of prenatally diagnosed trisomy 16 mosaicism. *Prenat Diagn.* 2006;26(6):548–58.
67. Sparks TN, Thao K, Norton ME. Mosaic trisomy 16: what are the obstetric and long-term childhood outcomes? *Genet Med Off J Am Coll Med Genet.* 2017;19(10):1164–70.
68. Chen S, Lau TK, Zhang C, Xu C, Xu Z, Hu P, et al. A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing. *Prenat Diagn.* 2013;33(6):584–90.
69. Wapner RJ, Babiarz JE, Levy B, Stosic M, Zimmermann B, Sigurjonsson S, et al. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. *Am J Obstet Gynecol.* 2015;212(3):332.e1-332.e3329.
70. Yin A, Peng C, Zhao X, Caughey BA, Yang J, Liu J, et al. Noninvasive detection of fetal subchromosomal abnormalities by semiconductor sequencing of maternal plasma DNA. *Proc Natl Acad Sci U S A.* 2015;112(47):14670–5.

Tables

Table 1. Study cohort clinical characteristics

Group	Gestational age at birth (w), mean (range)	Maternal age at birth (y), mean (range)	Sex, N male (%)	Birthweight (S.D.), mean (range)	Twins, N (%)	PE, N (%)
<i>Vancouver cohort - Total samples</i>						
Control (N=136)	39.2 (30.1-41.9)	34.3 (23.8-45.8)	68 (50)	0.1 (-1.2-2.7)	11 (8)	0 (0)
SGA (N=71)	35.3 (23.6-41.7)*	35.2 (23.1-41.0)	34 (48)	-1.9 (-3.6- -1.2)*	12 (17)	31 (44)
<i>Subset of samples for CNV profiling</i>						
Control (N=24)	39.3 (38.0-41.4)	34.8 (30.2-40.5)	13 (54)	0.01 (-1.1-2.2)	0 (0)	0 (0)
SGA (N=29)	34.9 (24.0-40.6)*	34.4 (23.9-42.9)	18 (62)	-1.9 (-3.0- -0.6)*	0 (0)	11 (38)
<i>Toronto cohort - Total samples</i>						
Control (N=37)	37.1 (27.3-41.0)	32.9 (21-43)	19 (51)	0.28 (-1.1-1.5)	0 (0)	0 (0)
SGA (N=30)	34.0 (27.1-38.6)*	35.1 (25-44)	9 (30)	-2.2 (-3.5-1.2)*	5 (17)*	0 (0)

* $p < 0.05$, p -values calculated in comparison to respective control groups by Student's t-test for maternal age and birth weight, Mann-Whitney U-test for gestational age, and Fisher's exact test for all categorical variables. SGA, small-for-gestational age; PE, preeclampsia

Table 2. Summary of findings from detection of placental aneuploidy.

Study Group (N)	Balanced (M:F)	Unbalanced (M:F)	CGH/MLPA result	Inferred karyotype	CPM
Control (173)	171 (86:85)	2 (1:1)	Gain of X	47,XXX [‡]	No
			del(X/Yq)	46,XY,del(Yqter)	Unk.
SGA (101)	89 (39:50)	12 (4:8)	Gain of 7	47,XX,+7/46,XX [‡]	Yes
			Gain of 7	47,XY,+7/46,XY [‡]	Yes
			Gain of 2	47,XX,+2/46,XX [‡]	Yes
			Gain of 13	47,XX,+13/46,XX [‡]	Yes
			dup(7q),del(Xp)	46,XX,der(X) t(X;7)(p22.2;q21.2)/46,XX	Yes
			del(4q),dup(4p)	46,XY, der(4)del(4)(q34.2), dup(4)(p16.3p15.31)/46,XY	Yes
			Gain of 10, Gain of X	48,XXX,+10/47,XXX	Yes [‡]
			N/A	47,XY,+2/46,XY	Unk.
			N/A	46,XX,+i(15q)/46,XX	Unk.
			N/A	47,XX,+16/46,XX	Yes
			N/A	47,XX,+16/46,XX	Yes
N/A	47,XY,+16/46,XY	Yes			

[‡]Cases published in Robinson *et al.* 2010 (16); [‡]Constitutional trisomy X, CPM of trisomy 10. CGH, comparative genomic hybridization; MLPA, multiplexed ligation-dependent probe amplification; CPM, confined placental mosaicism; Unk., unknown/unable to confirm; N/A, not available (cases were only screened by microarray).

Table 3. Summary of load of CNVs in control and SGA placentas.

	Vancouver Cohort		Toronto Cohort	
	Control (N=24)	SGA [‡] (N=28)	Control (N=37)	SGA (N=25)
N CNVs	17 (11-25)	16 (9-27)	35 (20-57)	32 (22-52)
Gains	7 (1-11)	7 (1-14)	17 (9-38)	15 (8-36)
Losses	10 (4-20)	9 (3-17)	18 (9-33)	17 (10-29)
N rare CNVs	4 (1-10)	4 (2-10)	7 (1-29)	6 (1-19)
Gains	1 (0-6)	2 (0-6)	4 (0-22)	3 (0-16)
Losses	3 (0-7)	3 (0-9)	3 (0-12)	3 (0-6)
Cumul. size (Mb)	1.22 (0.44-3.43)	1.59 (0.57-5.12)	3.20 (1.25-7.86)	3.17 (1.63-5.80)
Gains	0.57 (0.03-1.32)	0.86 (0.03-2.85)	2.36 (1.06-6.97)	2.05 (0.97-5.11)
Losses	0.65 (0.06-2.92)	0.72 (0.11-3.45)	0.84 (0.18-2.33)	1.12 (0.36-4.19)
Cumul. size rare (kb)	219 (10-902)	327 (74-864)*	893 (38-3,652)	825 (19-3,329)
Gains	100 (0-781)	197 (0-819)	678 (0-3,460)	516 (0-2,937)
Losses	119 (0-485)	130 (0-517)	1,570 (0-5,776)	1,373 (0-4,516)

[‡] excludes outlier PM324. * $p < 0.05$, Mann-Whitney U-test. All values reported as mean (range). Cumul., cumulative

Table 4. Candidate CNVs with clinical relevance to SGA identified in study placentas.

Case ID	Sex	Study group	Genomic coordinates (hg19)	Size (kb)	CNV type	Genes	Category	CPM
7665	Female	SGA	2:121,092,278-121,914,455	822	Gain	<i>INHBB, GLI2</i>	VUS-likely pathogenic	No
6234	Female	SGA	16:67,150,183-67,615,830	466	Loss	<i>HSD11B2, CTCF</i> , 21 others	VUS-likely pathogenic	No
10506	Female	SGA	8:112,947,262-116,124,691	3,177	Loss	<i>CSMD3</i>	VUS-likely pathogenic	No

CPM, confined placental mosaicism; VUS, variant of uncertain significance